Stay updated with breaking news from Mina Sooch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Clinical-stage ophthalmic biopharmaceutical company Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its fourth-quarter and year-end financial results on March 30
Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy after 24 Weeks of Treatment Oral... | January 25, 2023
Nyxol demonstrated positive topline results in subjects with night vision disturbances in the phase 3 LYNX-1 pivotal clinical trial, Ocuphire Pharma announced in a press release.One hundred forty-five subjects who experienced night vision impairment were randomly assigned to receive either Nyxol (0.75% phentolamine ophthalmic solution) or placebo daily for 14 days. The primary endpoint was the
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early...
FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...